ClinicalTrials.gg
Active, not recruitingNCT04291885I-MATUpdated Oct 7, 2026

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

A Phase 2 interventional study of Avelumab and Placebo in Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I and Merkel Cell Carcinoma, Stage II, sponsored by Melanoma and Skin Cancer Trials Limited. Active, not recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Melanoma and Skin Cancer Trials Limited · Phase 2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Carcinoma, Merkel Cell with a site in Australia — 4 open to participants now, 10 under way, none of them phase 3. Carcinoma, Merkel Cell · Australia.

Enrollment
8th of 19
122 · median 115
Started
2020
with 2 others
Phase 2
7 of 20
1 open now
Registered
11th of 20
by date
Lead sponsor
2 of 20
Melanoma and Skin Cancer Trials Limited

Among the 20 studies in Carcinoma, Merkel Cell with a site in Australia, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 11th registered.

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 39 are open to participants now.

Browse Carcinoma, Merkel Cell studies →

Open to participants now

4 of the 20 studies in Carcinoma, Merkel Cell with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 33 Carcinoma, Merkel Cell studies recruiting now, 26 (79%) set no upper age limit and none (0%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Carcinoma, Merkel Cell with a site in Australia, or all of them as a file.
02

Study summary

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

Read the detailed description

The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The primary aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy regimen for patients with stage I-III MCC, post a range of definitive loco-regional treatment options.

03

Conditions studied

  • Merkel Cell Carcinoma
  • Merkel Cell Carcinoma, Stage I
  • Merkel Cell Carcinoma, Stage II
  • Merkel Cell Carcinoma, Stage III
  • Neuroendocrine Tumors
  • Carcinoma Neuroendocrine Skin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed Merkel cell carcinoma (MCC) which is either:

    • clinical stage I;
    • pathological stage I with positive LVSI only;
    • clinical or pathological stage II (including IIA and IIB);
    • clinical or pathological stage III (including IIIA and IIIB).
  2. Absence of distant disease on baseline 18-Fludeoxyglucose (18FDG) - Positron Emission Tomography (PET) / Computed Tomography (CT) scan.
  3. 18 years of age or older.
  4. (ECOG) of 0 - 2.
  5. Willing and able to provide written and comply with all study requirements.
  6. Adequate haematological, liver and renal function as determined by the screening laboratory values outlined in the protocol obtained within 14 days prior to randomisation.
  7. Agreeable to collection of archival tumour material. Where possible, the most recently acquired tumour specimen should be provided.
  8. Women of child bearing potential () must have a negative serum or urine pregnancy test within 72 hours prior to the start of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Ongoing or recent (within 5 years) evidence of significant disease that required treatment with systemic treatments, which may suggest significant risk for immune-related adverse events.
  2. Prior treatment with an agent that blocks the /PD-L1 pathway.
  3. Previous cancer immunotherapy, specifically interferon, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways are not permitted.
  4. Prior treatment with other immune-modulating agents that was within fewer than 28 days prior to the first dose of Avelumab.
  5. Active infection requiring antibiotics within 7 days of cycle 1 day 1 of study drug dose.
  6. Active tuberculosis.
  7. Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  8. Uncontrolled infection with or virus (HBV or HCV) infection; Patients with previously successfully treated HCV, with positive anti-HCV antibody but undetectable (HCV) ribonucleic acid (RNA) levels are allowed on trial.
  9. Current use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical , or local steroid injection ; b. systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. steroids as premedication for reactions
  10. Any systemic anti-cancer treatment (chemotherapy, targeted systemic therapy) or standard of care, within 28 days of the first dose of Avelumab or planned to occur during the study period. Patients receiving bisphosphonates or denosumab will not be excluded.
  11. Pregnant or breastfeeding.
  12. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic organising pneumonia), or evidence of active pneumonitis on screening chest CT scan).
  13. Uncontrolled cardiac disease including not limited to symptomatic congestive heart failure, unstable angina pectoris, life-threatening cardiac arrhythmia
  14. Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies ( v5 Grade 3).
  15. Use of within 28 days of first dose of Avelumab.
  16. Any acute or chronic psychiatric problems that, in the opinion of the Investigator, make the patient ineligible for participation due to compliance concerns.
  17. Patients with prior allogeneic stem cell or solid organ transplantation.
  18. Patients who are involuntarily incarcerated.
  19. Evidence of other in the past 3 years, with exception of tumours with negligible risk of or death.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Avelumab

    6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)

    Drug: Avelumab

  • Placebo comparator
    Placebo

    6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)

    Drug: Placebo

Interventions

  • Avelumab IV infusion

    Also known as: anti-PD-L1, Bavencio

  • DrugPlacebo

    Placebo IV infusion

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival (RFS)

    Recurrence-free survival (RFS) as the primary endpoint, is anticipated to be analysed over an average planned follow-up of 3.5 years. An analysis of RFS at the 24 month time point of follow-up will also be conducted as it is anticipated that the minimum follow-up for participants will be 24 months and the sample size rationale utilises RFS rates at 24 months in historical controls. RFS is defined as the time from treatment initiation until the first date of any signs or symptoms of recurrence of tumour.

    Time frame: 24 Months

Secondary outcomes

  1. Overall survival (OS)

    Overall survival rates at 12 and 24 months. Overall survival is defined as the time from treatment initiation to the date of death due to any cause.

    Time frame: 24 Months

  2. Disease-specific survival (DSS)

    Disease-specific survival at 24 months from treatment initiation. Disease-specific survival is the percentage of participants who have not died from Merkel Cell Carcinoma

    Time frame: 24 Months

  3. Rate of loco-regional failure free survival (LRFFS)

    Rate of loco-regional failure free survival (LRFFS) is defined as the time from treatment initiation to the first recurrence of the loco-regional tumour.

    Time frame: 24 Months

  4. Distant metastasis-free survival (DMFS)

    DMFS is defined as the time from treatment initiation to the first evidence of distant metastatic disease.

    Time frame: 24 Months

  5. Treatment toxicity and tolerability as assessed by NCI CTCAE v5.0

    Rate of treatment-related adverse events (AEs). Safety will be measured by serious adverse events (SAEs) and AEs assessed as per NCI CTCAE v5.0, including immune-related adverse events.

    Time frame: 24 Months

  6. Patient-reported quality of life (QoL) as assessed by FACT-M questionnaire

    FACT-M form (version 4) will be utilised. This will include patient-reported questions relating to physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and additional patient concerns which are measured from 0-4 (Not at all - Very Much).

    Time frame: 24 Months

Other outcomes

  1. Rate of Merkel cell polyomavirus positivity in stage I-III Merkel cell carcinoma

    To identify Merkel cell polyomavirus MCPyV virus status. To correlate viral aetiology-rate of Merkel cell polyomavirus (MCPyV) positivity in pathology specimens in stage I-III Merkel cell carcinoma with outcome from adjuvant treatment.

    Time frame: 24 Months

  2. Correlating whole exome sequencing (WES) and ribonucleic acid (RNA) expression with immunotherapy response and outcomes in early stage MCC

    To evaluate the relationship between somatic mutations in cancer genes or the total mutation burden of the cancer with immunotherapy response and outcome following adjuvant therapy.

    Time frame: 24 Months

  3. Correlating immune infiltrates by multiplex immunohistochemistry (IHC) with survival endpoints

    To address whether immune infiltrates and PD-L1 expression are associated with survival.

    Time frame: 24 Months

  4. Utility of circulating biomarkers in predicting recurrence in early stage MCC

    To identify predictive biomarkers for response and resistance to immunotherapy in patients with stage I-III MCC using archival tissue and peripheral blood.

    Time frame: 24 Months

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Nov 2026, 72 months after the start.

Of 33 phase 2 interventional studies under Carcinoma, Merkel Cell, half reached primary completion within 92 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 138. This study's planned 72 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2027 → Nov 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2020
First posted
Mar 2, 2020
StartActual
Oct 26, 2020
Primary completionEst.
Nov 10, 2026was Apr 2027
CompletionEst.
Apr 30, 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 1, 2027→Nov 10, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Apr 1, 2027→Nov 10, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04291885
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Responsible party
Sponsor
First posted
Mar 2, 2020
Start date
Oct 26, 2020
Primary completion
Nov 10, 2026 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 7, 2026

Study contacts

A/Prof Wen Xu, MBBS, FRACP
study chair · Princess Alexandra Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avelumab

Start the discussion